[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594490":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":25,"locations":31,"responsibleParty":217,"collaborators":11,"id":219,"slug":220,"hasResults":221,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":11,"eligibilityCriteria":225,"healthyVolunteers":221,"sex":226,"minAge":227,"maxAge":11,"enrollmentInfo":228,"targetDuration":11,"studyType":231,"phases":232,"briefSummary":234,"conditions":235,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},{"fullName":5,"class":6},"Aktis Oncology, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[225Ac]Ac-AKY-1189","EXPERIMENTAL",null,[13,14],"Drug: [225Ac]Ac-AKY-1189 (therapeutic)","Drug: [64Cu]Cu-AKY-1189 (imaging)",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","[225Ac]Ac-AKY-1189 (therapeutic)","\\[225Ac\\]Ac-AKY-1189 Injection",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"[64Cu]Cu-AKY-1189 (imaging)","\\[64Cu\\]Cu-AKY-1189 Injection",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Janet Horton, MD","CONTACT","978-208-3986","AKY-1189-01inquiries@aktisoncology.com",[32,51,65,80,94,111,126,141,155,172,187,202],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-117.97729,34.13945,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":11,"email":50},"Abhishek Tripathi, MD","626-256-4673","atripathi@coh.org",{"facility":52,"status":34,"city":53,"state":36,"zip":54,"country":38,"countryCode":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Hoag Memorial Hospital Presbyterian","Irvine","92618",{"type":41,"coordinates":56},[57,58],-117.82311,33.66946,{"lat":58,"lon":57},[61],{"name":62,"role":28,"phone":63,"phoneExt":11,"email":64},"Ryan Reddy, MD","949-764-4577","ryan.reddy@hoag.org",{"facility":66,"status":34,"city":67,"state":68,"zip":69,"country":38,"countryCode":39,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Biogenix Molecular, LLC","Miami","Florida","33165",{"type":41,"coordinates":71},[72,73],-80.19366,25.77427,{"lat":73,"lon":72},[76],{"name":77,"role":28,"phone":78,"phoneExt":11,"email":79},"Jerry Joseph","(786)791-1799","jjoseph@cira-health.com",{"facility":81,"status":34,"city":82,"state":68,"zip":83,"country":38,"countryCode":39,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Advent Health Medical Group Radiation Oncology at Central Florida","Orlando","32804",{"type":41,"coordinates":85},[86,87],-81.37924,28.53834,{"lat":87,"lon":86},[90],{"name":91,"role":28,"phone":92,"phoneExt":11,"email":93},"Bridget Koontz, MD","407-303-2024","Bridget.koontz.MD@adventhealth.com",{"facility":95,"status":34,"city":96,"state":97,"zip":98,"country":38,"countryCode":39,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"University of Iowa","Iowa City","Iowa","52242",{"type":41,"coordinates":100},[101,102],-91.53017,41.66113,{"lat":102,"lon":101},[105,109],{"name":106,"role":28,"phone":107,"phoneExt":11,"email":108},"Kristin West","319-356-3656","kristin-gaimari-varner@uiowa.edu",{"name":110,"role":28,"phone":11,"phoneExt":11,"email":11},"Kristin Plichta, MD, PhD",{"facility":112,"status":34,"city":113,"state":114,"zip":115,"country":38,"countryCode":39,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"University of Kansas","Westwood","Kansas","66205",{"type":41,"coordinates":117},[118,119],-94.6169,39.04056,{"lat":119,"lon":118},[122],{"name":123,"role":28,"phone":124,"phoneExt":11,"email":125},"KUCC Nurse Navigation","913-945-7552","CTNurseNav@kumc.edu",{"facility":127,"status":34,"city":128,"state":129,"zip":130,"country":38,"countryCode":39,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"United Theranostics","Glen Burnie","Maryland","21061",{"type":41,"coordinates":132},[133,134],-76.62469,39.16261,{"lat":134,"lon":133},[137],{"name":138,"role":28,"phone":139,"phoneExt":11,"email":140},"Amanda Huggins","667-467-3669","clinicaltrial@unithera.com",{"facility":142,"status":34,"city":143,"state":144,"zip":145,"country":38,"countryCode":39,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"BAMF Health","Grand Rapids","Michigan","49503",{"type":41,"coordinates":147},[148,149],-85.66809,42.96336,{"lat":149,"lon":148},[152],{"name":11,"role":28,"phone":153,"phoneExt":11,"email":154},"616-330-2735","ResearchClinicalTeam@bamfhealth.com",{"facility":156,"status":34,"city":157,"state":157,"zip":158,"country":38,"countryCode":39,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Icahn School of Medicine at Mt. Sinai","New York","10029",{"type":41,"coordinates":160},[161,162],-74.00597,40.71427,{"lat":162,"lon":161},[165,169],{"name":166,"role":28,"phone":167,"phoneExt":11,"email":168},"Sophia Rhoads","317-903-4419","Sophia.rhoads@mssm.edu",{"name":170,"role":28,"phone":11,"phoneExt":11,"email":171},"Patricia Acon","patricia.acon@mssm.edu",{"facility":173,"status":34,"city":174,"state":175,"zip":176,"country":38,"countryCode":39,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"UPMC","Pittsburgh","Pennsylvania","15232",{"type":41,"coordinates":178},[179,180],-79.99589,40.44062,{"lat":180,"lon":179},[183],{"name":184,"role":28,"phone":185,"phoneExt":11,"email":186},"Samantha Demko, RN, BSN","412-623-1400","albesl@upmc.edu",{"facility":188,"status":34,"city":189,"state":190,"zip":191,"country":38,"countryCode":39,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":41,"coordinates":193},[194,195],-95.36327,29.76328,{"lat":195,"lon":194},[198],{"name":199,"role":28,"phone":200,"phoneExt":11,"email":201},"Natalie Velez","713-792-1478","navelez@mdanderson.org",{"facility":203,"status":34,"city":204,"state":205,"zip":206,"country":38,"countryCode":39,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"type":41,"coordinates":208},[209,210],-111.89105,40.76078,{"lat":210,"lon":209},[213],{"name":214,"role":28,"phone":215,"phoneExt":11,"email":216},"Sklyler Johnson","801-585-0255","Skyler.johnson@hci.utah.edu",{"type":218,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100594490","phase-1-a-study-of-225acac-aky-1189-in-patients-with-solid-tumors-100594490",false,"NCT07020117","A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors","NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Histologic or cytologic confirmation of locally advance or metastatic disease\n* Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1\n* ECOG Performance Status of 0 or 1\n* Adequate end-organ function\n* Ability to give informed consent and comply with study requirements\n* Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids\n* Documented disease progression on prior line of therapy for metastatic disease\n\nExclusion Criteria:\n\n* Prior treatment with a therapeutic radiopharmaceutical\n* Prior treatment with a Nectin-4 targeted therapy, except enfortumab vedotin\n* Received an investigational agent within the previous 28days\n* Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy in the 3 weeks prior to study treatment\n* Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity","ALL","18 Years",{"count":229,"type":230},150,"ESTIMATED","INTERVENTIONAL",[233],"PHASE1","This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\\[225Ac\\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.",[236,237,238,239,240,241,242],"Urothelial Carcinoma Bladder","Triple Negative Breast Cancer (TNBC)","Hormone Receptor Positive Breast Adenocarcinoma","Non Small Cell Lung Cancer","Cervical Adenocarcinoma","Colorectal Adenocarcinoma","Head and Neck Cancer","2026-07-09",{"date":245,"type":246},"2026-07-10","ACTUAL",{"date":248,"type":246},"2025-08-22",{"date":250,"type":230},"2032-06",{"name":5,"class":6},12]